Other Information
−Removed: On May 12, 2026, the Company filed a Certificate of Correction (the “Certificate of Correction”) to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) that was previously filed on April 1, 2026.
−Removed: The Certificate of Amendment erroneously stated the number of authorized shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) as 200,000,000 (two hundred million).
−Removed: As corrected by the Certificate of Correction, the total number of authorized shares of Common Stock is two billion (2,000,000,000).
EXHIBIT INDEX
−Removed: PLUS THERAPEUTICS, INC.
+Added: CERENOME, INC.
Exhibit Number
10 unchanged sentences
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on April 1, 2026
−Removed: Certificate of Correction to the Amended and Restated Certificate filed with the Delaware Secretary of State on May 12, 2026
−Removed: Amended and Restated Bylaws of Plus Therapeutics, Inc.
+Added: Certificate of Correction to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on May 12, 2026
+Added: Certificate of Amendment to Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State effective August 3, 2026
+Added: Second Amended and Restated Bylaws of Cerenome, Inc.
Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock
3 unchanged sentences
Form of Common Stock Certificate
−Removed: Form of Pre-Funded Warrant
+Added: Form of May 2024 Pre-Funded Warrant
Form of Amendment and Restatement of the May 2024 Series A Warrant
Form of Amendment and Restatement of the May 2024 Series B Warrant
−Removed: Form of Pre-Funded Warrant
−Removed: Form of Warrant issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc.
+Added: Form of February 2025 Pre-Funded Warrant
+Added: Form of Warrant issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Cerenome, Inc.
and the purchasers named therein
−Removed: Form of Pre-Funded Warrant
+Added: Form of March 2025 Pre-Funded Warrant
Form of Amended March 2025 Series B Warrant
Form of Warrant, dated January 15, 2026
+Added: Daniels Employment Agreement, effective April 20, 2026
+Added: Equity Distribution Agreement, by and between the Company and Canaccord Genuity LLC, dated as of June 1, 2026
+Added: First Amendment to Lease, by and between LG 1 Property Owner LP and Cerenome, Inc., dated as of August 10, 2026
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-1.04(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
6 unchanged sentences
* In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No.
−Removed: 34‑47986, the certifications furnished in Exhibits 31.1, 31.2 and 32.1 hereto are deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates them by reference.
+Added: 34‑47986, the certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates them by reference.
+Added: Portions of this document have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: PLUS THERAPEUTICS, INC.
+Added: CERENOME, INC.
+Added: August 14, 2026
President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)
/s/ Andrew Sims
+Added: August 14, 2026
Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.